Rimeporide

Rimeporide
Systematic (IUPAC) name
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine
Clinical data
Legal status
  • Experimental
Identifiers
CAS Number 187870-78-6
ATC code None
PubChem CID 9799487
ChemSpider 7975252
UNII QH6B4V5743
ChEMBL CHEMBL2107802
Chemical data
Formula C11H15N3O5S2
Molar mass 333.38 g·mol−1

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation.[1] it has been granted orphan drug status by the European Medicines Agency.[2]

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1 (NHE-1). While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces sodium and calcium overload in cells of Duchenne patients.[1]

History

Rimeporide was designed as a treatment for chronic heart failure. It was unsuccessful in Phase I clinical trials, but was tolerated well by volunteers. Subsequently, the drug was sold to EspeRare, a Swiss nonprofit organisation[3] that aims at developing drugs for rare diseases. As of May 2015, the substance is in preclinical development for Duchenne.[1]

See also

Other drugs for Duchenne muscular dystrophy

References

  1. 1 2 3 Spreitzer, Helmut (26 May 2015). "Neue Wirkstoffe – Rimeporid". Österreichische Apothekerzeitung (in German) 69 (11): 12.
  2. ↑ "EspeRare’s Rimeporide receives Orphan Drug Designation in Duchenne Muscular Dystrophy". EspeRare. 4 May 2015.
  3. ↑ "Our mission and vision". EspeRare. Retrieved 23 July 2015.


This article is issued from Wikipedia - version of the Sunday, July 26, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.